Potent peptidic fusion inhibitors of influenza virus

doi:10.1126/science.aan0516

Title: Potent peptidic fusion inhibitors of influenza virus

Full Record
Similar

Abstract

Influenza therapeutics with new targets and mechanisms of action are urgently needed to combat potential pandemics, emerging viruses, and constantly mutating strains in circulation. We report here on the design and structural characterization of potent peptidic inhibitors of influenza hemagglutinin. The peptide design was based on complementarity-determining region loops of human broadly neutralizing antibodies against the hemagglutinin (FI6v3 and CR9114). The optimized peptides exhibit nanomolar affinity and neutralization against influenza A group 1 viruses, including the 2009 H1N1 pandemic and avian H5N1 strains. The peptide inhibitors bind to the highly conserved stem epitope and block the low pH–induced conformational rearrangements associated with membrane fusion. These peptidic compounds and their advantageous biological properties should accelerate the development of new small molecule– and peptide-based therapeutics against influenza virus.

Authors:

; ; ; ; ; ; ; ; ; ; ; Vogels, Ronald; Friesen, Robert H. E.; Goudsmit, Jaap; ;

Publication Date:: Thu Sep 28 00:00:00 EDT 2017

Research Org.:: Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS)

Sponsoring Org.:: National Institutes of Health (NIH)

OSTI Identifier:: 1408128

Resource Type:: Journal Article

Resource Relation:: Journal Name: Science; Journal Volume: 358; Journal Issue: 6362

Country of Publication:: United States

Language:: ENGLISH

Subject:: 60 APPLIED LIFE SCIENCES

Citation Formats


                    Kadam, Rameshwar U., Juraszek, Jarek, Brandenburg, Boerries, Buyck, Christophe, Schepens, Wim B.  G., Kesteleyn, Bart, Stoops, Bart, Vreeken, Rob J., Vermond, Jan, Goutier, Wouter, Tang, Chan, Vogels, Ronald, Friesen, Robert H.  E., Goudsmit, Jaap, van Dongen, Maria J.  P., and Wilson, Ian A. Potent peptidic fusion inhibitors of influenza virus.  United States: N. p., 2017. 
        Web.  doi:10.1126/science.aan0516.

Copy to clipboard


                    Kadam, Rameshwar U., Juraszek, Jarek, Brandenburg, Boerries, Buyck, Christophe, Schepens, Wim B.  G., Kesteleyn, Bart, Stoops, Bart, Vreeken, Rob J., Vermond, Jan, Goutier, Wouter, Tang, Chan, Vogels, Ronald, Friesen, Robert H.  E., Goudsmit, Jaap, van Dongen, Maria J.  P., & Wilson, Ian A. Potent peptidic fusion inhibitors of influenza virus.  United States.  doi:10.1126/science.aan0516.

Copy to clipboard


                    Kadam, Rameshwar U., Juraszek, Jarek, Brandenburg, Boerries, Buyck, Christophe, Schepens, Wim B.  G., Kesteleyn, Bart, Stoops, Bart, Vreeken, Rob J., Vermond, Jan, Goutier, Wouter, Tang, Chan, Vogels, Ronald, Friesen, Robert H.  E., Goudsmit, Jaap, van Dongen, Maria J.  P., and Wilson, Ian A. Thu .  
        "Potent peptidic fusion inhibitors of influenza virus".  United States.  
        doi:10.1126/science.aan0516.

Copy to clipboard


                    
@article{osti_1408128,

  title        = {Potent peptidic fusion inhibitors of influenza virus},

  author       = {Kadam, Rameshwar U. and Juraszek, Jarek and Brandenburg, Boerries and Buyck, Christophe and Schepens, Wim B.  G. and Kesteleyn, Bart and Stoops, Bart and Vreeken, Rob J. and Vermond, Jan and Goutier, Wouter and Tang, Chan and Vogels, Ronald and Friesen, Robert H.  E. and Goudsmit, Jaap and van Dongen, Maria J.  P. and Wilson, Ian A.},

  abstractNote = {Influenza therapeutics with new targets and mechanisms of action are urgently needed to combat potential pandemics, emerging viruses, and constantly mutating strains in circulation. We report here on the design and structural characterization of potent peptidic inhibitors of influenza hemagglutinin. The peptide design was based on complementarity-determining region loops of human broadly neutralizing antibodies against the hemagglutinin (FI6v3 and CR9114). The optimized peptides exhibit nanomolar affinity and neutralization against influenza A group 1 viruses, including the 2009 H1N1 pandemic and avian H5N1 strains. The peptide inhibitors bind to the highly conserved stem epitope and block the low pH–induced conformational rearrangements associated with membrane fusion. These peptidic compounds and their advantageous biological properties should accelerate the development of new small molecule– and peptide-based therapeutics against influenza virus.},

  doi          = {10.1126/science.aan0516},

  journal      = {Science},

  number       = 6362,

  volume       = 358,

  place        = {United States},

  year         = {Thu Sep 28 00:00:00 EDT 2017},

  month        = {Thu Sep 28 00:00:00 EDT 2017}

}

Copy to clipboard

Journal Article:

DOI: 10.1126/science.aan0516

Other availability

Find in Google Scholar

Search WorldCat to find libraries that may hold this journal

Save / Share:

Export Metadata

Save to My Library

Polymerized liposomes containing C-glycosides of sialic acid: Potent inhibitors of influenza virus in vitro infectivity

Spevak, W. ; Bednarski, M.D. ; Nagy, J.O. ; ... - Journal of the American Chemical Society; (United States)

The surface lectin of the influenza virus, hemagglutinin, binds to terminal [alpha]-glycosides of N-acetylneuraminic acid (NeuAc) on cell-surface glycoproteins and glycolipids. Viral binding to cells expression terminal NeuAc residues can be inhibited by [alpha]-O-glycosides of NeuAc (O-sialosides). Recently, dramatic enhancements in the inhibition of viral adhesion to erythrocytes have been achieved using synthetic polyvalent sialosides. In this communication, the authors report that polymerized liposomes containing [alpha]-C-glycosides of sialic acid are potent inhibitors of influenza virus in vitro infectivity. Their results also indicate that the capacity to inhibit hemagglutination does not necessarily reflect the capacity to inhibit in vitro infectivity. 14more » refs., 1 tab.« less
DOI: 10.1021/ja00056a047
Substitution of the transmembrane domain of Vpu in simian-human immunodeficiency virus (SHIV{sub KU1bMC33}) with that of M2 of influenza A results in a virus that is sensitive to inhibitors of the M2 ion channel and is pathogenic for pig-tailed macaques

Hout, David R. ; Gomez, Melissa L. ; Pacyniak, Erik ; ... - Virology

The Vpu protein of human immunodeficiency virus type 1 has been shown to shunt the CD4 receptor molecule to the proteasome for degradation and to enhance virus release from infected cells. The exact mechanism by which the Vpu protein enhances virus release is currently unknown but some investigators have shown that this function is associated with the transmembrane domain and potential ion channel properties. In this study, we determined if the transmembrane domain of Vpu could be functionally substituted with that of the prototypical viroporin, the M2 protein of influenza A virus. We constructed chimeric vpu gene in which themore »« less
DOI: 10.1016/J.VIROL.2005.0
A potent broad-spectrum protective human monoclonal antibody crosslinking two haemagglutinin monomers of influenza A virus

Wu, Ying ; Cho, MyungSam ; Shore, David ; ... - Nat. Commun.
DOI: 10.1038/ncomms8708
Identification of a novel multiple kinase inhibitor with potent antiviral activity against influenza virus by reducing viral polymerase activity

Sasaki, Yutaka ; Kakisaka, Michinori ; Chutiwitoonchai, Nopporn ; ... - Biochemical and Biophysical Research Communications

Highlights: • Screening of 50,000 compounds and subsequent lead optimization identified WV970. • WV970 has antiviral effects against influenza A, B and highly pathogenic viral strains. • WV970 inhibits viral genome replication and transcription. • A target database search suggests that WV970 may bind to a number of kinases. • KINOMEscan screening revealed that WV970 has inhibitory effects on 15 kinases. - Abstract: Neuraminidase inhibitors are the only currently available influenza treatment, although resistant viruses to these drugs have already been reported. Thus, new antiviral drugs with novel mechanisms of action are urgently required. In this study, we identified amore »« less
DOI: 10.1016/J.BBRC.2014.05.058
Universal antibodies against the highly conserved influenza fusion peptide cross-neutralize several subtypes of influenza A virus

Hashem, Anwar M. ; Department of Microbiology, Faculty of Medicine, King Abdulaziz University, Jeddah ; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON ; ... - Biochemical and Biophysical Research Communications

Research highlights: {yields} The fusion peptide is the only universally conserved epitope in all influenza viral hemagglutinins. {yields} Anti-fusion peptide antibodies are universal antibodies that cross-react with all influenza HA subtypes. {yields} The universal antibodies cross-neutralize different influenza A subtypes. {yields} The universal antibodies inhibit the fusion process between the viruses and the target cells. -- Abstract: The fusion peptide of influenza viral hemagglutinin plays a critical role in virus entry by facilitating membrane fusion between the virus and target cells. As the fusion peptide is the only universally conserved epitope in all influenza A and B viruses, it couldmore »« less
DOI: 10.1016/J.BBRC.2010.11.030